Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2006-10-10
2006-10-10
Nickol, Gary (Department: 1642)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S133100, C530S387100, C530S388100
Reexamination Certificate
active
07118744
ABSTRACT:
The invention relates to the use of an immunogen selected from the group consisting of(i) an anti-p53 mAb;(ii) a fragment of an anti-p53 mAb;(iii) a peptide based on a CDR of the heavy or light chain of an anti-p53 mAb, which peptide is capable of eliciting antibodies to p53; and(iv) a DNA molecule coding for the variable (V) region of an anti-p53 mAb in a suitable gene delivery vehicle, for the preparation of a pharmaceutical composition useful for induction of anti-tumor immunity in mammals, for activating an enhanced immune response to a p53 molecule in mammals, and/or for induction of immune responses to mutated and wild-type forms of a p53 in mammals. The use of anti-p53 mAbs and novel peptides based on the CDR2 and CDR3 of the heavy chains and CDR3 of the light chains of different anti-p53 mAbs are disclosed.
REFERENCES:
patent: 5068177 (1991-11-01), Carson et al.
patent: 5874209 (1999-02-01), Karin et al.
patent: 0438312 (1991-07-01), None
patent: WO 92/13970 (1992-08-01), None
patent: WO 93/18792 (1993-09-01), None
patent: WO 96/01126 (1996-01-01), None
patent: WO 97/04092 (1997-02-01), None
patent: WO 98/1885 (1998-05-01), None
Jannot et al., BBRC 230:242-246, 1997.
Erez-Alon et al., Cancer Res. 58:5447-5452, 1998.
Cruse et al (Illustrated dictionary of Immunology, CRC Press, 1995, p. 148.
Zusman et al. The Cancer Journal. 1997, 10:116-120.
Jannot et al. BBRC, 1997, 230:242-246.
Cohen, “Natural Id-Anti-Id Networkds and the Immunological Homunculus”, inTheories of Immune Networks(Atlan et al, ed.), Springer-Verlag; Heidelberg (1989) pp. 6-12.
Cohen, “The cognitive paradigm and the immunological homunculus”,Immunol Today13(12):490-494 (1992).
El-Deiry et al, “Definition of a consensus binding site for p53”,Nature Genet1(4):45-49 (1992).
Foord et al, “A DNA binding domain is contained in the C-terminus of wild type p53 protein”,Nucleic Acids Res19(19):5191-5198 (1991).
Gannon et al, “Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form”,EMBO J9(5):1595-1602 (1990).
Harlow et al, “Monoclonal antibodies specific for simian virus 40 tumor antigens”,J Virol39:861-869 (1981).
Hollstein et al, “p53 mutations in human cancers”,Science253:49-53 (1991).
Houbiers et al, “In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53”,Eur J Immunol23:2072-2077 (1993).
Jannot et al, “Characterization of scFv-421, a Single-Chain Antibody Targeted to p53”,Biochem Biophys Res Comm230:242-246 (1997).
Lee et al, “p53 and its 14Kda C-terminal domain recognize primary DNA damage in the form of insertion/deletin”,Cell, 81:1013-1020 (1995).
Lubin et al, “Analysis of p53 30 antibodies in patients with various cancers define B-cell epitopes of human p53): distribution on primary structure and exposure on protein surface”,Cancer Res53:5872-5876 (1993).
Nicholson et al, “Anti-tumor immune responses following monoclonal antibody therapy of ovarian cancer”,Proc Ann Meet Am Asso Cancer Res, vol. 38, (XP002081861( (1997).
Nisonoff et al, “Idiotypes: concepts and applications”,J Immunol147:2429-2438 (1991).
Paul,Fundamental Immunology, Raven Press, NY, Chapter 8, p. 242 (1993).
Ruiz et al, “Idiotypic immunization induces immunity to mutated p53 and tumor rejection”,Nature Med4(6):710-712 (1998).
Schlichtholz et al, “The immune response to p53) in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot”,Cancer Res52:6380-6384 (1992).
Soussi T, “The humoral response to the tumor suppressor gene product p53) in human cancer. Implications for diagnosis and theapy”,Immunol Today17:354-356 (1996).
Stevenson et al, “Idiotypic DNA vaccines against B-cell lymphoma”,Immunol Rev145:211-228 (1995).
Tilkin et al, “Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer”,Eur J Immunol25:1765-1769 (1995).
Wolkowicz et al, “The DNA binding activity of wild type p53 is modulated by blocking its various antigenic epitopes”,Oncogene10:1167-1174 (1995).
Yanuck et al, “A mutant p53 tumor suppressor protein is a target for peptide-induced CD8+cytotoxic T-cells”,Cancer Res53:3257-3261 (1993).
Zusman et al, “Tumor-Suppressor effects of anti-p53 IgG on chemical induced colon cancer in rats”,Cancer J10(2):116-120 (1997).
Cohen Irun R
Erez-Alon Neta
Herkel Johannes
Rotter Varda
Ruiz Pedro
Aeder Sean E
Nickol Gary
Winston & Strawn LLP
Yeda Research and Development Co. Ltd.
LandOfFree
Immunogenic compositions for induction of anti-tumor immunity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunogenic compositions for induction of anti-tumor immunity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunogenic compositions for induction of anti-tumor immunity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3714455